PRRT2 and mantle cell lymphoma: The cause of the ibrutinib resistance in MCL cells has been shown to be due to constitutive activation of the non-canonical NF-κB signaling pathway, which is not targeted by BTK or PKC inhibitors, in contrast to the canonical NF-κB signaling, which is sensitive to BTK or PKC inhibitors [19].